Dexpanthenol
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
- Dexpanthenol
- Pharmacist Assessment Report
- Dexpanthenol: topical pantothenic acid precursor → anorectal stricture
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Dexpanthenol: topical pantothenic acid precursor → anorectal stricture
One-Sentence Summary
Dexpanthenol is a topical provitamin of pantothenic acid (vitamin B5), which is a precursor of coenzyme A and supports skin and mucosal repair. The TxGNN model predicts it may be useful for anorectal stricture, but no clinical trials and no publications directly study this condition, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Anorectal stricture |
| TxGNN Prediction Score | 0.9972 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, dexpanthenol is converted in the body to pantothenic acid, a precursor of coenzyme A. Coenzyme A is involved in epithelial repair and wound healing, and topical dexpanthenol is used to support skin barrier function and hydration.
A role in mucosal healing could plausibly relate to anorectal stricture, where tissue repair and scarring are central. This link is hypothetical. No study in the compiled data tests dexpanthenol in strictures, and the TxGNN score reflects a model-derived association only. The score is not evidence of clinical benefit.
Clinical Trial Evidence
Currently no related clinical trials registered for anorectal stricture.
One Phase 3 trial of dexpanthenol-containing cream relates to a different condition (a predicted skin rash indication ranked lower), so it does not support the main prediction:
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01136005 | Phase 3 | Completed | 160 | Bepanthen cream vs cetomacrogol cream for prevention of papulopustular eruption in patients receiving EGFR inhibitors; results not provided |
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 4510J | SebiRinse | Cream 200 g | Not recorded in the local data |
The only listed product is a topical cream. No rectal or anal formulation appears in the local data, so route compatibility with an anorectal indication is unconfirmed.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. No drug interactions were found in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score (0.9972) and a plausible but unproven tissue-repair rationale. No trial or publication directly studies anorectal stricture, so the evidence level is L5.
To proceed, the following is needed:
- Systematic literature search for dexpanthenol in anorectal or mucosal stricture and healing
- Mechanism of action data to support the proposed link
- Assessment of whether a suitable rectal or anal formulation exists, since the only local product is a topical cream
- Product Information review for warnings and contraindications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.